Abstract:Background: Immunotherapy has emerged as a novel strategy for cancer treatment following surgery, radiotherapy, and chemotherapy. Immune checkpoint blockade and Chimeric antigen receptor (CAR)-T cell therapies have been successful in clinical trials. Cancer cells evade immune surveillance by hijacking inhibitory pathways via overexpression of checkpoint genes. The Cluster of Differentiation 47 (CD47) has emerged as a crucial checkpoint for cancer immunotherapy by working as a "don't eat me" signal and suppressing innate immune signaling. Furthermore, CD47 is highly expressed in many cancer types to protect cancer cells from phagocytosis via binding to SIRPα on phagocytes. Targeting CD47 by either interrupting the CD47-SIRPα axis or combing with other therapies has been demonstrated as an encouraging therapeutic strategy in cancer immunotherapy. Antibodies and small molecules that target CD47 have been explored in pre- and clinical trials. However, formidable challenges such as the anemia and palate aggregation cannot be avoided because of the wide presentation of CD47 on erythrocytes. Aim of view: This review summarizes the current knowledge on the regulation and function of CD47, and provides a new perspective for immunotherapy targeting CD47. It also highlights the clinical progress of targeting CD47 and discusses challenges and potential strategies. Key scientific concepts of review: This review provides a comprehensive understanding of targeting CD47 in cancer immunotherapy, it also augments the concept of combination immunotherapy strategies by employing both innate and adaptive immune responses.

Targeting the CD47-SIRPα Signaling Axis: Current Studies on B-cell Lymphoma Immunotherapy

Targeting CD47-SIRPα Axis for Hodgkin and Non-Hodgkin Lymphoma Immunotherapy

Targeting CD47-SIRPa axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

The CD47-SIRPα Axis is a Promising Target for Cancer Immunotherapies

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment

Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy

Insights into CD47/SIRPα Axis-Targeting Tumor Immunotherapy

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Deciphering the role of CD47 in cancer immunotherapy

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-cell Lymphoma.

CD47 as a promising therapeutic target in oncology

The landscape overview of CD47-based immunotherapy for hematological malignancies

Building on the Backbone of CD47-based Therapy in Cancer: Combination Strategies, Mechanisms, and Future Perspectives

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Targeting CD47 for Cancer Immunotherapy

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.

CD47: Beyond an immune checkpoint in cancer treatment